Surgical Perspective on Earlier Intervention in Severe Aortic Regurgitation: Insights From the Medical Student Bench

I read with great interest the recent article by Djordjevic et al, ¹ “Rethinking surgical timing in aortic regurgitation: a case for earlier intervention,” which challenges the conservative thresholds endorsed by current ESC/EACTS guidelines. ¹ As a third-year medical student with an interest in cardiovascular medicine and surgery, I was particularly struck by the discussion of latent left ventricular (LV) dysfunction and its potential to precipitate cardiogenic shock (CS) despite preserved systolic performance.

The authors underscore the surgical urgency at the intersection of operative decision-making and the often-invisible biological clock of LV remodeling. From a training perspective, we are taught to rely on LV ejection fraction (LVEF) ≤50% or indexed LV end-systolic dimension (LVESDi) >25 mm/m² as primary surgical triggers. However, as the cited Brussels cohort ² and AVIATOR registry data ³ show, such thresholds may represent the “point of no return,” with postoperative survival compromised once LVEF drops below 55% or symptomatic deterioration ensues.

I also appreciated the emphasis on advanced imaging modalities and biomarkers. ¹ Strain imaging and cardiac magnetic resonance imaging with tissue characterization could be incorporated into earlier risk stratification, particularly in patients with borderline LVEF (50%–55%) and subtle exercise intolerance. In my view, this aligns with a precision medicine framework, allowing intervention to be individualized before irreversible myocyte loss and fibrotic replacement occur.

Furthermore, I note that CS in aortic regurgitation (AR) is not merely an acute “event,” but the culmination of protracted LV adaptation, volume overload, and a deceptive period of compensated hemodynamics. In the undergraduate curriculum, AR is often portrayed as a gradual, symptom-driven disease; this paper reinforces the need to teach that sudden decompensation can occur even in apparently stable patients.

The proposed multicenter randomized trial comparing early versus guideline-triggered surgery is essential. While the surgical community debates the ideal threshold, patients in the “gray zone” of preserved function but progressive LV dilation remain vulnerable. I believe that redefining “early” surgery, perhaps to include select asymptomatic patients with LVEF 50%–55%, LVESDi >20 mm/m², or abnormal strain, could reduce the incidence of CS and improve long-term outcomes.

In conclusion, Djordjevic et al ¹ present compelling evidence that should prompt both clinicians and trainees to critically re-evaluate the timing of surgical referral in AR. As a future physician, I see this surgical reframing as an opportunity to integrate novel diagnostics, nuanced risk assessment, and patient-centered decision-making into our evolving approach to valvular heart disease.